Eupraxia fully recruits EoE study with about $126m in the bank

Eupraxia Pharmaceuticals has finished recruiting for the mid-stage portion of RESOLVE, its study of EP-104GI in eosinophilic esophagitis (EoE), and says it holds enough cash to operate into the second half of 2028. The company announced both points on 10 November 2026 alongside its third-quarter results.

The trial enrolled the 120 patients it targeted. It is randomised and includes a placebo arm, and the company expects the first look at its results in December 2026. The summary available to CompePharma does not specify the endpoints, the date within the month or the dosing regimens being compared, so the scale of any effect the company needs to show is unclear.

On the financial side, Eupraxia reported a third-quarter net loss of $15.2 million. Cash and short-term investments stood at roughly $126 million. By the company's own account, that balance carries it past the December readout and well into 2028. The source gives no regulatory timetable or next-stage trial plan, so it is not clear what that runway is meant to pay for beyond this study.

The data now being tested come from an earlier open-label study, in which 64% of patients stayed in clinical remission over 52 weeks. With no placebo group in that work, the figure cannot separate the drug's effect from other influences. The randomised comparison due next month is therefore the first evidence of this kind for EP-104GI in EoE.